How To Reduce Eligibility Risk And Prevent Protocol Deviations

Incorrect participant enrollment is a primary operational risk that jeopardizes data credibility and patient safety. With the FDA’s December 2024 guidance classifying enrollment errors as "important protocol deviations," the pressure is on to move from reactive reporting to proactive prevention. Centralized eligibility review offers a structured solution, ensuring every participant strictly meets inclusion and exclusion criteria through systematic workflows, source evidence verification, and independent medical review.

Implementing these controls eliminates enrollment-based deviations without stalling study timelines. By replacing manual, high-friction processes with a "finely tuned choreography" of data routing and real-time audit trails, teams can standardize decision-making across global sites. Adopting this technology-enabled approach not only aligns with the latest regulatory expectations but also safeguards the ultimate goal of any clinical trial: reliable, high-quality data.